Topics

Promising Phase 3 Results With New Oral MS Drug Ponesimod

06:21 EDT 3 Oct 2019 | Medscape

The new drug reduced relapse rate, active lesions, and fatigue symptoms vs teriflunomide in the OPTIMUM trial.
Medscape Medical News

Original Article: Promising Phase 3 Results With New Oral MS Drug Ponesimod

NEXT ARTICLE

More From BioPortfolio on "Promising Phase 3 Results With New Oral MS Drug Ponesimod"

Quick Search

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...